BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26845602)

  • 1.  Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis.
    Hilscher M; Enders FB; Carey EJ; Lindor KD; Tabibian JH
    Ann Hepatol; 2016; 15(2):246-53. PubMed ID: 26845602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis.
    Stanich PP; Björnsson E; Gossard AA; Enders F; Jorgensen R; Lindor KD
    Dig Liver Dis; 2011 Apr; 43(4):309-13. PubMed ID: 21251891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated Serum Bilirubin Level Correlates With the Development of Cholangiocarcinoma, Subsequent Liver Transplantation, and Death in Patients With Primary Sclerosing Cholangitis.
    Haseeb A; Siddiqui A; Taylor LJ; Cox K; Adler DG
    J Clin Gastroenterol; 2016; 50(5):431-5. PubMed ID: 26927495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
    Lindor KD; Kowdley KV; Luketic VA; Harrison ME; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Keach J; Mooney J; Sargeant C; Braaten J; Bernard T; King D; Miceli E; Schmoll J; Hoskin T; Thapa P; Enders F
    Hepatology; 2009 Sep; 50(3):808-14. PubMed ID: 19585548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary sclerosing cholangitis: patients with a rising alkaline phosphatase at annual follow-up.
    Charatcharoenwitthaya P; Lindor KD
    Clin Gastroenterol Hepatol; 2007 Jan; 5(1):32-6. PubMed ID: 17234554
    [No Abstract]   [Full Text] [Related]  

  • 6. Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value.
    de Vries EM; Wang J; Leeflang MM; Boonstra K; Weersma RK; Beuers UH; Geskus RB; Ponsioen CY
    Liver Int; 2016 Dec; 36(12):1867-1875. PubMed ID: 26945698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses.
    van Hoogstraten HJ; Wolfhagen FH; van de Meeberg PC; Kuiper H; Nix GA; Becx MC; Hoek AC; van Houte DP; Rijk MC; Salemans JM; Scherpenisse J; Schrijver M; Smit AM; Spoelstra P; Stadhouders PH; Tan TG; Hop WC; ten Kate FJ; vanBerge-Henegouwen GP; Schalm SW; van Buuren HR
    J Hepatol; 1998 Sep; 29(3):417-23. PubMed ID: 9764988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase.
    Murillo Perez CF; Harms MH; Lindor KD; van Buuren HR; Hirschfield GM; Corpechot C; van der Meer AJ; Feld JJ; Gulamhusein A; Lammers WJ; Ponsioen CY; Carbone M; Mason AL; Mayo MJ; Invernizzi P; Battezzati PM; Floreani A; Lleo A; Nevens F; Kowdley KV; Bruns T; Dalekos GN; Gatselis NK; Thorburn D; Trivedi PJ; Verhelst X; Parés A; Janssen HLA; Hansen BE;
    Am J Gastroenterol; 2020 Jul; 115(7):1066-1074. PubMed ID: 32618657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis.
    Al Mamari S; Djordjevic J; Halliday JS; Chapman RW
    J Hepatol; 2013 Feb; 58(2):329-34. PubMed ID: 23085647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The resurgence of serum alkaline phosphatase as a surrogate biomarker for prognosis in primary sclerosing cholangitis.
    Talwalkar JA; Chapman RW
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):847-9. PubMed ID: 23591287
    [No Abstract]   [Full Text] [Related]  

  • 11. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis.
    Lindström L; Hultcrantz R; Boberg KM; Friis-Liby I; Bergquist A
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):841-6. PubMed ID: 23353641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort.
    Bakhshi Z; Hilscher MB; Gores GJ; Harmsen WS; Viehman JK; LaRusso NF; Gossard AA; Lazaridis KN; Lindor KD; Eaton JE
    J Gastroenterol; 2020 May; 55(5):523-532. PubMed ID: 31932891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.
    Olsson R; Boberg KM; de Muckadell OS; Lindgren S; Hultcrantz R; Folvik G; Bell H; Gangsøy-Kristiansen M; Matre J; Rydning A; Wikman O; Danielsson A; Sandberg-Gertzén H; Ung KA; Eriksson A; Lööf L; Prytz H; Marschall HU; Broomé U
    Gastroenterology; 2005 Nov; 129(5):1464-72. PubMed ID: 16285948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis: Predictors of Gamma Glutamyltransferase Normalization and Favorable Clinical Course.
    Deneau M; Perito E; Ricciuto A; Gupta N; Kamath BM; Palle S; Vitola B; Smolka V; Ferrari F; Amir AZ; Miloh T; Papadopoulou A; Mohan P; Mack C; Kolho KL; Iorio R; El-Matary W; Venkat V; Chan A; Saubermann L; Valentino PL; Shah U; Miethke A; Lin H; Jensen MK
    J Pediatr; 2019 Jun; 209():92-96.e1. PubMed ID: 30878206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of cholestatic liver disease].
    Pleşa A
    Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):733-6. PubMed ID: 14756010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis.
    Tabibian JH; Enders F; Imam MH; Kolar G; Lindor KD; Talwalkar JA
    Ann Hepatol; 2014; 13(3):384-9. PubMed ID: 24756015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection?
    Hay JE
    Liver Transpl Surg; 1998 Sep; 4(5 Suppl 1):S9-17. PubMed ID: 9742489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary sclerosing cholangitis in critically ill patients has a poor outcome but lower tumour incidence than primary sclerosing cholangitis.
    Kirstein MM; Book T; Manns MP; von Hahn T; Voigtländer T
    United European Gastroenterol J; 2020 Jul; 8(6):716-724. PubMed ID: 32366182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.
    Lammers WJ; van Buuren HR; Hirschfield GM; Janssen HL; Invernizzi P; Mason AL; Ponsioen CY; Floreani A; Corpechot C; Mayo MJ; Battezzati PM; Parés A; Nevens F; Burroughs AK; Kowdley KV; Trivedi PJ; Kumagi T; Cheung A; Lleo A; Imam MH; Boonstra K; Cazzagon N; Franceschet I; Poupon R; Caballeria L; Pieri G; Kanwar PS; Lindor KD; Hansen BE;
    Gastroenterology; 2014 Dec; 147(6):1338-49.e5; quiz e15. PubMed ID: 25160979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study.
    Eaton JE; Nelson KM; Gossard AA; Carey EJ; Tabibian JH; Lindor KD; LaRusso NF
    Scand J Gastroenterol; 2019 May; 54(5):633-639. PubMed ID: 31131678
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.